Oral altretamine used as salvage therapy in recurrent ovarian cancer

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 368-371

  Chan, John K ^a   Loizzi, Vera ^b   Manetta, Alberto ^b   Berman, Michael L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Altretamine; Recurrent ovarian cancer; Salvage therapy

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PLATINUM; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ABDOMINAL RADIOGRAPHY; ADULT; AGED; ANAMNESIS; ANAPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FEVER; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GYNECOLOGIC SURGERY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LAPAROTOMY; LONG TERM CARE; NEEDLE BIOPSY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; OVARY TUMOR; PARAAORTIC LYMPH NODE; PELVIS LYMPHADENECTOMY; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SALVAGE THERAPY; SIDE EFFECT; SURGICAL TECHNIQUE; TUMOR RECURRENCE;

EID: 0742307238     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.017     Document Type: Article

References (12)

1. Alberts D.S. Treatment of refractory and recurrent ovarian cancer. Semin. Oncol. 26:1999;8-14.
2. Markman M.B.M. Second-line treatment of ovarian cancer. The Oncologist. 5:2000;26-35.
3. Rothenberg M.L., Liu P.Y., Wilczynski S., Hannigan E.V., Weiner S.A., Weiss G.R.et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol. Oncol. 82:2001;317-322.
4. Rustin G.J., Nelstrop A.E., Crawford M., Ledermann J., Lambert H.E., Coleman R.et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J. Clin. Oncol. 15:1997;172-176.
5. Rosen G.F., Lurain J.R., Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol. Oncol. 27:1987;173-179.
6. Manetta A., Tewari K., Podczaski E.S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol. Oncol. 66:1997;20-26.
7. Malik I.A. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn. J. Clin. Oncol. 31:2001;69-73.
8. Stehman F.B., Ehrlich C.E., Callangan M.F. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Gynecol. Oncol. 17:1984;189-195.
9. Vergote I., Himmelmann A., Frankendal B., Scheistroen M., Vlachos K., Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol. Oncol. 47:1992;282-286.
10. Markman M., Blessing J.A., Moore D., Ball H., Lentz S.S. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 69:1998;226-229.
11. Keldsen N., Havsteen H., Vergote I., Bertelsen K., Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol. Oncol. 88:2003;118-122.
12. Moore D.H., Valea F., Crumpler L.S., Fowler W.C. Jr. Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol. Oncol. 51:1993;109-112.